GeneBio Systems
EGFR ELISA kit (Human)
EGFR ELISA kit (Human)
SKU:SEA757Hu
Couldn't load pickup availability
Size: 96Tests
# of Times Cited in literature: 14
Prepare Time: 1-3 days(please inquire for mutiple units)
Target Name: EGFR
Target Full Name: Epidermal Growth Factor Receptor
Alternative Names: ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
Target Species: Human
Uniprot: P00533
Gene ID: 1956
Featured Series: SE kit
Featured Series Function: Detects protein (regular version)
Specificity: Reactive with Human EGFR / Epidermal Growth Factor Receptor
Method: Colormetric
Detection principle: Double-antibody Sandwich
Detection range: 3.12-200ng/mL
Sensitivity: 1.21ng/mL
Assay Time: 3h
Sample Size: 100uL
Recommended/Predicted Sample Types: Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates and other Biological Fluids
Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%
Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Epidermal Growth Factor Receptor (EGFR) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Epidermal Growth Factor Receptor (EGFR) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100
Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)
Shelf-life: 12 months
Specificity: This assay has high sensitivity and excellent specificity for detection of Epidermal Growth Factor Receptor (EGFR). No significant cross-reactivity or interference between Epidermal Growth Factor Receptor (EGFR) and analogues was observed.
Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.
Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Epidermal Growth Factor Receptor (EGFR). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Epidermal Growth Factor Receptor (EGFR). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Epidermal Growth Factor Receptor (EGFR), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Epidermal Growth Factor Receptor (EGFR) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
Research Area: CD & Adhesion molecule;Tumor immunity;
References Citing This Product: Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer
Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism …
GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands
LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway
Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection.
EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform
Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers
Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile
Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents
Synthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters …
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine
Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung
Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives
Humoral immune response to epidermal growth factor receptor in lung cancer
Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents
Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors
Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies
